Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (abre nova janela)

Barillari G, Pasca S, Barillari A, De Angelis V.

Fonte‎: Blood Transfus 2012;10(1):87-94.

Indexado‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (abre nova janela)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (abre nova janela)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Fonte‎: Chest 2012;141(2 Suppl):e326S-50S.

Indexado‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (abre nova janela)

Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin. (abre nova janela)

Flordal PA.

Fonte‎: Eur J Anaesthesiol Suppl 1997;14:38-41.

Indexado‎: PubMed 9088834

https://www.ncbi.nlm.nih.gov/pubmed/9088834 (abre nova janela)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (abre nova janela)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Fonte‎: Lancet 2015;385(9982):2077-87.

Indexado‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (abre nova janela)

How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. (abre nova janela)

Goodnough LT, Shander A.

Fonte‎: Blood 2011;117(23):6091-9.

Indexado‎: PubMed 21411756

DOI‎: 10.1182/blood-2010-11-316075

https://www.ncbi.nlm.nih.gov/pubmed/21411756 (abre nova janela)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (abre nova janela)

Hanke AA, Joch C, Görlinger K.

Fonte‎: Br J Anaesth 2013;110(5):764-72.

Indexado‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (abre nova janela)

Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature. (abre nova janela)

Jaben EA, Mulay SB, Stubbs JR.

Fonte‎: J Intensive Care Med 2015;30(1):3-7.

Indexado‎: PubMed 25492811

DOI‎: 10.1177/0885066613487298

https://www.ncbi.nlm.nih.gov/pubmed/25492811 (abre nova janela)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (abre nova janela)

Levi M, Eerenberg E, Kamphuisen PW.

Fonte‎: J Thromb Haemost 2011;9(9):1705-12.

Indexado‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (abre nova janela)

Emergency reversal of warfarin anticoagulation. (abre nova janela)

Lin Y, Callum J.

Fonte‎: CMAJ 2010;182(18):2004.

Indexado‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (abre nova janela)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (abre nova janela)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Fonte‎: Thromb Haemost 2012;108(2):217-24.

Indexado‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (abre nova janela)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (abre nova janela)

Mo Y, Yam FK.

Fonte‎: Pharmacotherapy 2015;35(2):198-207.

Indexado‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (abre nova janela)

Idarucizumab for dabigatran reversal - full cohort analysis. (abre nova janela)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Fonte‎: N Engl J Med 2017;377(5):431-41.

Indexado‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (abre nova janela)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (abre nova janela)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Fonte‎: Anesth Analg 2011;113(4):703-10.

Indexado‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (abre nova janela)

Oral anticoagulation in surgical procedures: risks and recommendations. (abre nova janela)

Torn M, Rosendaal FR.

Fonte‎: Br J Haematol 2003;123(4):676-82.

Indexado‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (abre nova janela)

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. (abre nova janela)

Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW.

Fonte‎: Blood 2012;119(9):2172-4.

Indexado‎: PubMed 22383791

DOI‎: 10.1182/blood-2011-11-393587

https://www.ncbi.nlm.nih.gov/pubmed/22383791 (abre nova janela)